Rival Teva pharmceuticals said it would buy Barr for $66.50 / share.
Barr Laboratories, Europe completed the acquisition of PLIVA, a generic pharmaceutical producer headquartered in Zagreb, Croatia.
Barr's Portia, a generic oral contraceptive, was approved in Canada.